IRB approval obtained for the SwissCardIA cohort study

In July 2026, SwissCardIA received official approval from the Cantonal Research Ethics Committees of Vaud (CER-VD) and Geneva (CCER), marking a major milestone in the study’s development.

Designing a large-scale population study requires balancing scientific ambition with rigorous ethical and regulatory standards. Over several months, the research team developed a comprehensive protocol addressing scientific validity, participant safety, informed consent, and the protection of sensitive health and genetic data.

This approval reflects the team’s commitment to conducting high-quality, responsible research while safeguarding participants’ rights, privacy, and well-being.

With this important milestone achieved, SwissCardIA moves one step closer to launching recruitment and advancing cardiovascular prevention research.